UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 1200 Prospect Street, Suite ...

INmune Bio Inc. (NASDAQ:INMB) Q4 2019 Results Conference Call March 11, 2020 11:00 AM ET Company Participants R.J. Tesi - CEO David Moss - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Swayampakula Ramakanth - H. C. Wainwright Carl Byrnes - Northland Securities Daniel Carlson - Tailwinds Research David Bautz - Zacks Investment Research Paul Morris - Alliance Global Partners Michael Erwin - Universe Securities Operator Greetings and welcome to the INmune Bio’s Fourth Quarter and F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ___________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

IViunine Bio HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases INMB INVESTOR PRESENTATION January 2020 FORWARD LOOKING STATEMENTS This presentation contains "forward-looking statements" Forward-looking statements reflect our current view about future events. When used in this presentation, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 1200 Prospect Street, Suite 525 La Jolla, CA 92037 (Address of principal executive of ice) (Zip code) FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 (858) 964-3720 OR (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO S ...

uneBio INMB non-confidential3Q19.v2 � Forward-Looking Statements This presentation contains "forward-looking statements" Forward-looking statements reflect our current view about future events. When used in this presentation, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contain ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 1200 Prospect Street, Suite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 1224 Prospect Street, Suite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. David Moss 1224 Prospect Street, Suite 150 La Jolla, CA 92037 For the fiscal year ended: December 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ___________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as spe ...

Nasdaq: INMB February 2019.v8 Forward-Looking Statements This presentation contains "forward‐looking statements" Forward‐looking statements reflect our current view about future events. When used in this presentation, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements, include, but are not limited to, statements contained in th ...